帕丘利酒精对AD小鼠的认知功能障碍的影响和机制,由Aβ1-42寡合体通过AMPK/mTOR途径诱导

相关实验视频

Updated: Jun 21, 2025

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices
04:41

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices

Published on: July 14, 2010

23.2K

Li-Ting Lin1, Shu-Ting Zhang1, Bao-Ling Shang2

  • 1School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, PR China.

Brain research bulletin
|July 12, 2024
PubMed
概括

帕丘利酒精 (PA) 在阿尔茨海默病 (AD) 鼠标模型中显著改善记忆缺陷. 通过AMPK/mTOR途径减少神经炎症并增强自,这为AD提供了潜在的治疗策略.

关键词:
阿尔茨海默氏症的疾病是阿尔茨海默氏症.自自是一种自的过程.Aβ(142) 寡合体中的一个.认知障碍 认知障碍是一种认知障碍.神经炎症是一种神经炎症.帕丘利葡萄酒的酒精含量是多少

更多相关视频

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits08:01

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Published on: March 16, 2016

42.3K
Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps10:19

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Published on: August 14, 2016

9.3K

相关概念视频

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
461
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
177